Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2.

"Conflicts of interest J.W.M. is a consultant to Gilead Sciences and holds shares or share options in Co-Crystal Pharma, Inc., Abound Bio, Inc. and Infectious Disease Connect. K.D.M. and J.L.J. declare no conflicts of interest."

"Financial support and sponsorship Research reported in this publication was supported by a grant from the AIDS Clinical Trials Group Network (ACTG) to the University of Pittsburgh Virology Specialty Laboratory funded by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) under Award Number UM1 AI106701. This project has also been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract Number 75N91019D00024, Task Order Number 75N91019F00129. This work was funded by the University of Pittsburgh through a Clinical and Translational Science Institute (CTSI) award supported by the National Institutes of Health through grant number UL1TR001857. The work was also funded by a University of Pittsburgh Medical Center (UPMC) Chief Medical Scientific Officer (CMSO) award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. Funding for this review is provided by the National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases."